Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Review

IGF-binding protein 2 is a candidate target of therapeutic potential in cancer

Authors: Xiaofeng Yao, Shanshan Sun, Xuan Zhou, Wenyu Guo, Lun Zhang

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Insulin-like growth factor (IGF)-binding protein 2(IGFBP2), a key member of IGF family, has been reported as a notable oncogene in most human epithelium cancers. Increasing evidences suggested that IGFBP2 might be a candidate target of therapuetic potential by regulating key cancer metastasis and invasion-associated signaling networks, but there is still confusion about the mechanism on how IGFBP2 takes part in these processes. In this review, we summarized the current points of view that IGFBP2 functions in signaling pathways during tumorigenesis and tumor progression and discussed its potential clinical applications as a therapeutic target.
Literature
1.
Cao Y et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015;136(10):2418–26.PubMedCrossRef
2.
Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28.PubMedCrossRef
3.
Šunderić M et al. Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. Exp Mol Pathol. 2014;96(1):48–53.PubMedCrossRef
4.
Ahani N et al. Expression of insulin-like growth factor binding protein-2 (IGFBP-2) gene in negative and positive human cytomegalovirus glioblastoma multiforme tissues. Med Oncol. 2014;31(2):812.PubMedCrossRef
5.
Kricker JA et al. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology. 2003;144(7):2807–15.PubMedCrossRef
6.
Fukushima T, Kataoka H. Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res. 2007;27(6A):3685–92.PubMed
7.
Rohrmann S et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Br J Cancer. 2012;106(5):1004–10.PubMedPubMedCentralCrossRef
8.
Rowlands MA et al. Serum insulin-like growth factors and mortality in localized and advanced clinically detected prostate cancer. Cancer Causes Control. 2012;23(2):347–54.PubMedCrossRef
9.
Liou JM et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and pognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 2010;95(4):1717–25.PubMedCrossRef
10.
Ma J et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620–5.PubMedCrossRef
11.
Miyake H et al. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep. 2005;13(2):341–5.PubMed
12.
Wang H et al. Insulin-like growth factor binding protein2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 2003;63(15):4315–21.PubMed
13.
Carrick FE et al. BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J Biol Chem. 2001;276(29):27120–8.PubMedCrossRef
14.
Headey SJ et al. Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. J Mol Endocrinol. 2004;33(2):377–86.PubMedCrossRef
15.
16.
Galea CA et al. Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie. 2012;94(3):608–16.PubMedCrossRef
17.
Sitar T et al. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A. 2006;103(35):13028–33.PubMedPubMedCentralCrossRef
18.
Swain M et al. High-yield bacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2. Arch Biochem Biophys. 2010;501(2):195–200.PubMedPubMedCentralCrossRef
19.
Holmes KM et al. Insulin-like growth factor-binding protein 2-driven glioma progression isprevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kB network. Proc Natl Acad Sci U S A. 2012;109(9):3475–80.PubMedPubMedCentralCrossRef
20.
Wheatcroft SB et al. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and −2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20(4):153–62.PubMedCrossRef
21.
Kawai M et al. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem. 2011;286(16):14670–80.PubMedPubMedCentralCrossRef
22.
Mehrian-Shai R et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007;104(13):5563–8.PubMedPubMedCentralCrossRef
23.
Dunlap SM et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A. 2007;104(28):11736–41.PubMedPubMedCentralCrossRef
24.
Han S et al. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway. Br J Cancer. 2014;111(7):1400–9.PubMedPubMedCentralCrossRef
25.
Moore LM et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A. 2009;106(39):16675–79.PubMedPubMedCentralCrossRef
26.
Song SW et al. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci U S A. 2003;100(24):13970–5.PubMedPubMedCentralCrossRef
27.
Biernacka KM et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. 2013;20(5):741–51.PubMedCrossRef
28.
Uzoh CC et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 2011;104(10):1587–93.PubMedPubMedCentralCrossRef
29.
Neuhouser ML et al. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res. 2013;6(7):91–9.CrossRef
30.
Dean SJ et al. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negativebreast cancer. Am J Clin Pathol. 2014;141(3):323–33.PubMedCrossRef
31.
So AI et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 2008;14(21):6944–54.PubMedCrossRef
32.
Migita T et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol. 2010;176(4):1756–66.PubMedPubMedCentralCrossRef
33.
Zhang Y et al. Autoantibodies against insulin-like growth factor protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol. 2013;42(1):93–100.PubMed
34.
35.
Dawczynski K et al. Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant. 2006;37(6):589–94.PubMedCrossRef
36.
Renehan AG et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer. 2000;83(10):1344–50.PubMedPubMedCentralCrossRef
37.
Huang YF et al. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 2014;21(2):217–29.PubMedCrossRef
38.
Zhang L et al. Expression of IGFBP2 in gastric carcinoma and relationship with clinicpathologic parameters and cell proliferation. Dig Dis Sci. 2007;52(1):248–53.PubMedCrossRef
39.
40.
Wang H et al. Expression of insulin-like growth factorbinding protein 2 in melanocytic lesions. J Cutan Pathol. 2003;30(10):599–605.PubMedCrossRef
41.
Wang GK et al. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 2006;281(20):14085–91.PubMedCrossRef
42.
Mendes KN et al. JNK mediates insulin-like growth factor binding protein2/integrin alpha5-dependent glioma cell migration. Int J Oncol. 2010;37(1):143–53.PubMed
43.
Hsieh D et al. IGFBP2 promotes glioma tumor stem cell expansion and survival. Biochem Biophys Res Commun. 2010;397(2):367–72.PubMedCrossRef
44.
Foulstone EJ et al. Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology. 2013;154(5):1780–93.PubMedCrossRef
45.
Lu H et al. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 2013;12(12):2864–73.PubMedCrossRef
46.
Chen X et al. IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells. J Hematol Oncol. 2013;6(1):72.PubMedPubMedCentralCrossRef
47.
Ben-Shmuel A et al. Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression. Oncogene. 2013;32(27):3220–30.PubMedCrossRef
48.
Chakrabarty S, Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther. 2006;5(2):189–97.PubMedCrossRef
49.
Lancaster JM et al. High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006;16(4):1529–35.PubMedCrossRef
50.
Kang Z et al. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene. 2014;33(50):5697–705.PubMedCrossRef
51.
Das SK et al. MDA-9/Syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res. 2013;73(2):844–54.PubMedCrossRef
52.
Wang HM et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008;14(3):261–7.PubMedCrossRef
53.
Wieczorek E et al. Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 2015;36(1):163–75.PubMedCrossRef
54.
55.
Azar WJ et al. IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology. 152(9):3332–42.
56.
Zhu Z et al. Inhibition of PKR impairs angiogenesis through VEGF pathway. Am J Physiol Endocrinol Metab. 2015;308(6):E518–24.PubMedCrossRef
57.
Godard S et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003;63(20):6613–25.PubMed
58.
Jing T et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood. 2012;120(11):2330–9.CrossRef
59.
Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–54.PubMedCrossRef
60.
Conover CA. Isulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab. 2008;294(1):E10–4.PubMedCrossRef
61.
Shen X et al. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 2012;32(20):4116–30.PubMedPubMedCentralCrossRef
62.
Russo VC et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology. 2005;146(10):4445–55.PubMedCrossRef
63.
Lund J et al. Heparin-binding mechanism of the IGF2/IGF-binding protein 2 complex. J Mol Endocrinol. 2014;52(3):345–55.PubMedCrossRef
64.
Diehl D et al. IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer. 2009;124(9):2220–5.PubMedCrossRef
65.
Hang XP et al. Genetic variations in the IGF-IGFR-IGFBP axis confer susceptibility to lung and esophageal cancer. Genet Mol Res. 2014;13(1):2107–19.
66.
Png KJ et al. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2011;481(7380):190–4.PubMedCrossRef
67.
Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012;38(4):292–302.PubMedCrossRef
68.
Zhang CC et al. Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood. 2008;111(7):3415–23.PubMedPubMedCentralCrossRef
69.
Becher OJ et al. IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol. 2008;23(10):1205–13.PubMedPubMedCentralCrossRef
70.
Grimberg A et al. Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther. 2006;5(10):1408–14.PubMedPubMedCentralCrossRef
71.
Fukushima T et al. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007;282(25):18634–44.PubMedCrossRef
72.
Sun C et al. PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice. Neuroreport. 2014;25(3):177–83.PubMedPubMedCentralCrossRef
73.
Carnero A, Paramio JM. The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol. 2014;23(4):252.
74.
Mireuta M et al. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors. 2010;28(4):243–55.PubMedCrossRef
75.
Sheldrake HM, Patterson LH. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. J Med Chem. 2014;57(15):6301–15.PubMedCrossRef
76.
Sun CC et al. Integrins: players in cancer progression and targets in cancer therapy. Anticancer Drugs. 2014;25(10):1107–21.PubMedCrossRef
77.
Schütt BS et al. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 2004;32(3):859–68.PubMedCrossRef
78.
Wani AA et al. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kB /interleukin-6 signaling pathway. Oncogene. 2011;30(24):2778–88.PubMedCrossRef
79.
Yang M et al. The role of integrin-β/FAK in cyclic mechanical stimulation in MG-63 cells. Int J Clin Exp Pathol. 2014;7(11):7451–9.PubMedPubMedCentral
80.
Cox BD et al. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006;99(1):35–52.PubMedCrossRef
81.
82.
Tang MR et al. CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. Int J Clin Exp Med. 2014;7(11):4337–41.PubMedPubMedCentral
83.
Wu JX et al. Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis. PLoS One. 2014;9(12):E114746.PubMedPubMedCentralCrossRef
84.
Villani RM et al. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting igfbp2 activity. Cancer Prev Res. 2010;3(10):1222–34.CrossRef
85.
Sineva GS, Pospelov VA. β-Catenin in pluripotency: adhering to self-renewal or wnting to differentiate. Int Rev Cell Mol Biol. 2014;312:53–78.PubMedCrossRef
86.
Sehgal P et al. Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis. Mol Cancer. 2013;12:63.PubMedPubMedCentralCrossRef
87.
Miyako K et al. PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol. 2009;23(2):169–75.PubMedCrossRef
88.
Brana I et al. A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014;111(10):1932–44.PubMedPubMedCentralCrossRef
89.
Willky BA et al. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015;112(1):24–31.CrossRef
90.
Halvorson KG et al. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One. 2015;10(3):E0118926.PubMedPubMedCentralCrossRef
91.
McCaffery I et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 2013;19(15):4282–9.PubMedCrossRef
Metadata
Title
IGF-binding protein 2 is a candidate target of therapeutic potential in cancer
Authors
Xiaofeng Yao
Shanshan Sun
Xuan Zhou
Wenyu Guo
Lun Zhang
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4561-1

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells

Review

Adding Mendelian randomization to a meta-analysis—a burgeoning opportunity

Original Article

Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer

Review

The immunobiology of myeloid-derived suppressor cells in cancer

Original Article

Loss of protocadherin-17 (PCDH-17) promotes metastasis and invasion through hyperactivation of EGFR/MEK/ERK signaling pathway in hepatocellular carcinoma

Original Article

Circulating CD105 shows significant impact in patients of oral cancer and promotes malignancy of cancer cells via CCL20
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits